NCT05176067Unknown不适用
Department of Thoracic Oncology, Affiliated Tumor Hospital of Guizhou Medical University
Guizhou Medical University0 个研究点目标入组 88 人开始时间: 2021年12月30日最近更新:
适应症
试验速览
- 阶段
- 不适用
- 发起方
- 入组人数
- 88
- 主要终点
- PFS
研究概览
简要总结
To investigate whether radiotherapy combined with drug therapy is beneficial to non- oligometastatic stage IV NSCLC
详细描述
Group A (targeted therapy, immunotherapy, chemotherapy); The efficacy was evaluated after the second and fourth cycles of chemotherapy and immunotherapy; The efficacy of targeted therapy was evaluated every month; Group B (drug concurrent radiotherapy group: combined with thoracic primary tumor radiotherapy on the basis of targeted therapy, immune, chemotherapy ) The efficacy was evaluated after the second and fourth cycles of chemotherapy and immunotherapy; The efficacy of targeted therapy was evaluated every month; Radiographic evaluation was performed after radiotherapy for the primary lesion of the chest.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Single (Investigator)
盲法说明
Randomized Controlled Clinical Study
入排标准
- 年龄范围
- 18 Years 至 80 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •Non- small cell lung cancer patients diagnosed by pathology or cytology;
- •Patients with stage IV non-oligometastasitatic [Eighth Edition];
- •initial treatment (no previous treatment);
- •age 18 ~ 80 years old, physical condition score ECOG 0 ~ 2 or KPS ≥ 60;
- •distance metastatic lesions: more than 5 metastatic lesions ; mind when brain metastases; The number of pulmonary metastases does not affect lung function, and radiotherapy for primary and/or partial metastases may be performed;
- •no contraindications such as radiotherapy, EGFR-TKI, chemotherapy, and immunotherapy;
- •primary tumor radiotherapy requires IMRT technology; In the plan design, the primary tumor prescription dose (DTGTV) was given under the damage control threshold standard, and the prescription dose was ≥ 40Gy; During the planned evaluation, the prescription dose includes 100% GTV, and 90% prescription dose includes 98% ~ 100% PTV [planned target dose (DTP) ≥ 36Gy]; Normal lung (whole lung volume minus GTV volume) V20 ≤ 32%, MLD ≤ 20GY; (V20 ≤ 25% in radiotherapy for patients with ALK, Ros-1, met, etc.).
- •radiotherapy for metastatic tumors is three-dimensional radiotherapy technology (IMRT / SRT / SBRT / VMAT, etc.), SBRT.
- •the subject has no dysfunction of main organs, or the laboratory test indicators must meet the following requirements: hematology: it is within the normal range according to the standards of each laboratory; Cardiac function: normal range; Liver function: normal range; Renal function: normal range; Pulmonary function: FEV1 > 50%, mild to moderate impairment of pulmonary function.
- •The sign informed consent before treatment (radiotherapy, chemotherapy, immunization, targeted drug therapy);
- •patients have good compliance with the treatment and follow-up.
排除标准
- •Patients with pathological type, stage, and survival status that do not meet the inclusion criteria;
- •Stage IV NSCLC patients with serous effusion such as malignant pleural effusion and pericardial effusion;
- •Patients with extensive liver metastasis and intrapulmonary metastasis have seriously affected liver and lung function;
- •The patient had no control of hypertension, diabetes, unstable angina, history of myocardial infarction, or had congestive heart failure or cardiac arrhythmia in the past 12 months. Heart valve disease with definite clinical diagnosis; Disease activity period of bacterial, fungal, or viral infection; Mental disorders; Severe impairment of pulmonary function;
- •Pregnant and lactating patients;
- •Patients with a history of other active malignant tumors except for small cell lung cancer before enrollment; Non-melanoma skin basal cell carcinoma, cervical carcinoma in situ and cured early prostate cancer are excluded;
- •Patients with the allergic constitution and known or suspected allergy to any drug in the study without alternative drugs;
- •Patients with poor compliance;
- •The researcher believes that it is not suitable to participate in this experiment
结局指标
主要结局
PFS
时间窗: through study completion, an average of 1 year
The PFS of primary lung lesions and mediastinal metastatic lymph nodes
ORR
时间窗: through study completion, an average of 1-2 years
evaluate efficacy of drug therapy，efficacy of drug combination with radiotherapy with RECIST criteria.
次要结局
- Toxicity and side effecttion(through study completion, an average of 1-2 years)
研究者
Bing Lu
Chief physician
Guizhou Medical University
相似试验
已完成
2 期
FOcal Radiation for Oligometastatic Castration-rEsistant Prostate Cancer (FORCE)Prostate CancerNCT03556904University of Michigan Rogel Cancer Center14
已完成
不适用
Combination therapy of radiation and intratumoral directo injection of dendritic cells for advanced esophageal cancer, a phase I study.Esophageal cancerJPRN-UMIN000011079Chiba University6
进行中（未招募）
不适用
ow-doses radiotherapy and concomitant chemotherapy with pemetrexed in progression desease NSCLC: a dose-descalation phase II study - NDadvanced and/or metastatic NSCLCMedDRA version: 9.1Level: LLTClassification code 10059515Term: Non-small cell lung cancer metastaticEUCTR2008-003690-40-ITPOLICLINICO UNIVERSITARIO AGOSTINO GEMELLI
已完成
1 期
Combination of Weekly Chest Radiotherapy and Oral Navelbine for the Palliation of Advanced Non Small Cell Lung Cancer: A Phase I StudyCarcinoma, Non-Small-Cell LungNCT00256815Clinical Oncology Research Associates35
Unknown
2 期
Concurrent Radiotherapy and Weekly Chemotherapy of PF for Postoperative Locoregional Recurrence of Esophageal CancerEsophageal Squamous Cell CarcinomaNCT02325986Sun Yat-sen University46